[
    [
        {
            "time": "",
            "original_text": "48家上市公司械企，赚钱能力大比拼！",
            "features": {
                "keywords": [
                    "上市公司",
                    "器械企业",
                    "盈利能力"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗器械"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "48家上市公司械企，赚钱能力大比拼！",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "2018年医药行业中报总结分析：暂时无方向性自下而上选择为主",
            "features": {
                "keywords": [
                    "医药行业",
                    "中报",
                    "总结分析",
                    "自下而上"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2018年医药行业中报总结分析：暂时无方向性自下而上选择为主",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "以乐普生物为基石重点打造肿瘤免疫治疗平台",
            "features": {
                "keywords": [
                    "乐普生物",
                    "肿瘤免疫",
                    "治疗平台"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "以乐普生物为基石重点打造肿瘤免疫治疗平台",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【医药】乐普医疗：肿瘤免疫治疗布局高瞻远瞩，有望成为未来业绩重要驱动力",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "肿瘤免疫",
                    "布局",
                    "业绩驱动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】乐普医疗：肿瘤免疫治疗布局高瞻远瞩，有望成为未来业绩重要驱动力",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报:基药目录大调整,国务院下令增补187个品种",
            "features": {
                "keywords": [
                    "医药行业",
                    "基药目录",
                    "政策调整",
                    "增补品种"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报:基药目录大调整,国务院下令增补187个品种",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]